---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-097007"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:16:25.362333+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q2 net loss $48.1M; workforce cut 75%; ENLIGHTEN 1 subgroup positive

## Summary
- Q2 net loss $48.1M vs $15.6M YoY, including $22.8M right-of-use asset impairment and $6.5M restructuring charge.
- Cash $67.5M at June 30; expects runway into Q1 2026.
- Further analysis of ENLIGHTEN 1 shows LYR-210 improved 3CS score by 2.25 points (p=0.0058) vs sham in CRS with nasal polyps.
- Reduced workforce by ~75% (87 employees), halted manufacturing, paused LYR-220, and seeking subleases.
- ENLIGHTEN 1 extension results expected Q4 2024; ENLIGHTEN 2 topline results expected 1H 2025.

## SEC filing metadata
- accession: 0000950170-24-097007
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017024097007/0000950170-24-097007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017024097007/lyra-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-097007
- JSON: https://secwatch.observer/filing/0000950170-24-097007.json
- Plain text: https://secwatch.observer/filing/0000950170-24-097007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.